812 860
Critical revision of the manuscript for important intellectual content:
Babjuk, Compe´rat, Zigeuner, Sylvester, Burger, Mostafid, van Rhijn,
Gontero, Palou, Shariat.
Statistical analysis:
None.
Obtaining funding:
None.
Administrative, technical, or material support:
MacLennan, Lam, Yuan.
Supervision:
None.
Other:
None.
Financial disclosures:
Viktor Soukup and Otakar Cˇ apoun certifies that all
conflicts of interest, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultancies,
honoraria, stock ownership or options, expert testimony, royalties, or
patents filed, received, or pending), are the following:. O. Cˇ apoun—
honoraria or consultation fees from Janssen; company speaker
honorarium from Janssen, Ipsen, Astellas, Bayer, GSK, Janssen Pharma-
ceuticals; trial participation in Janssen, Astra Zeneca, Aragon Pharmaceu-
ticals; fellowship and travel grants from Janssen, Ipsen, Astellas, IPSEN,
GSK. T. Lam—company consultant for Pfizer, GSK, Astellas, Ipsen; company
speaker honorariumfromPfizer, GSK, Astellas, Ipsen.M. Babjuk—company
consultant for Astellas, Ipsen; company speaker honorarium from Ferring,
GSK; trial participation in Sotio. R. Zigeuner—company speaker honorari-
um from Pfizer, Bayer Healthcare, Roche, Novartis, Glaxo Smithkline,
Amgen, Ipsen; fellowship and travel grants from Bayer Healthcare, Pfizer,
Amgen, Novartis, Glaxo Smithkline, Astellas, Takeda; grants/research
supports from Bayer Healthcare; company consultant for Pfizer. M.
Burger—company consultant for Astellas, BMS, Ipsen Pharma, Janssen,
Pfizer, Springer, Thieme, Cepheid, Merk Sharp Dome; company speaker
honorarium from Astellas, BMS, Ipsen Pharma, Janseen, Pfizer, Springer,
Thieme, Bayer; trial participation in Photocure SA, Ipsen Pharma. H.
Mostafid—company consultant for Kyowa Hakko UK; company speaker
honorarium from Prostrakan; spouse/partner: Combat Medical; trial
participation in MSD. B. van Rhijn—company consultant for Astellas
2015. P. Gontero—company consultant for Andromedical; trial participa-
tion in Astellas. J. Palou—company consultant for Olympus, ALLERGAN,
IBSA, Olympus; company speaker honorarium from SANOFI-PASTEUR,
General Electric; trial participation in Combat Medical, Presurgy. S.
Shariat—company consultant for Astellas, Olympus, Wolff, Ipsen, Cepheid,
Janseen; company speaker honorarium from Lilly, Astellas, Ipsen,
Olympus, Wolff, Janssen; participation in Alere Inc. trials on NMP22;
participation in a company-sponsored speaker’s bureau: BMS, MSD,
Roche, Ipsen, Olympus; other: BMS, Janssen, Wolff, Olympus, Astellas,
MSD; honoraria or consultation fees from Astellas, Olympus, Wolff, Ipsen,
Janssen, Roche; trial participation in Roche, MSD, BMS; grants/research
supports from Astellas, Sanofi; patents: 2001 Shariat S. and Slawin K.:
Methods to determine prognosis after therapy for prostate cancer. U.S.
patent application serial number: Docket#60/266,976. Filed May 31,
2001; 2001 Shariat S., Lerner S. and Slawin K.: Methods to determine
prognosis after therapy for bladder cancer. U.S. patent application serial
number: Docket#675.003US1. Filed June 1, 2001; 2002 Shariat S., Slawin
K., Kattan M., and Scardino P.: Pre- and posttreatment nomograms for
predicting recurrence in patients with clinically localized prostate cancer
that includes the blood markers interlukin-6 soluble receptor and
transforming growth; 2003 Slawin K., Kattan M., Shariat S., Stephenson
A., and Scardino P.: Nomogram for predicting outcome of salvage
radiotherapy for suspected local recurrence of prostate cancer after
radical prostatectomy. US patent application serial number: Docket#. Fi;
2005 Shariat S. M. Roupreˆt—company consultant for Lilly, GSK, Astellas,
Takeda, Sanofi Pasteur, Ipsen; trial participation in GSK; company speaker
honorarium from Roche, Zambon; trial participation in Pfizer, Roche. V.
Soukup, E. Comperat, R. Sylvester, Steven MacLennan, Cathy Yuhong Yuan
have nothing to declare.
Funding/Support and role of the sponsor:
None.
References
[1]
Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superfi- cial bladder cancer. J Urol 2000;163:73–8.[2]
Sylvester RJ, van der Meijden A, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: 466–77.[3]
van Rhijn BW, van Leenders GJ, Ooms BC, et al. The pathologist’s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010;57:1052–7.[4]
Babjuk M, Bo¨hle A, Burger M, et al. EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–61.[5]
Mostofi FK, Sobin LH, Torloni H, editors. Histological typing of urinary bladder tumours. Geneva, Switzerland: World Health Organization; 1973.[6]
Bol MG, Baak JP, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291–4.[7]
Epstein JI, AminMB, Reuter VR, et al. TheWorld Health Organization/ International Society of Urological Pathology consensus classifica- tion of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–8.
[8]
Eble JN, Sauter G, Epstein JI, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004.[9]
Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. ed. 4 Lyon, France: WHO; 2016.[10]
Yorukoglu K, Tuna B, Dikicioglu E, et al. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 2003;443:734–40.
[11]
Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158: 280–6.[12]
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collabora- tion’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
[13]
Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. ed. 3 New York, NY: John Wiley & Sons; 2003.
[14]
Mangrud OM, Gudlaugsson E, Skaland I, et al. Prognostic compari- son of proliferation markers and World Health Organization 1973/ 2004 grades in urothelial carcinomas of the urinary bladder. Hum Pathol 2014;45:1496–503.
[15]
Holma¨ng S, Hedelin H, Anderstro¨m C, et al. Recurrence and pro- gression in low grade papillary urothelial tumors. J Urol 1999; 162:702–7.[16]
Mangrud OM, Waalen R, Gudlaugsson E, et al. Reproducibility and prognostic value of WHO 1973 and WHO 2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. PLoS One 2014; 9:e83192.
[17]
Holma¨ng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohisto- chemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124–8.
[18]
Gontero P, Gillo A, Fiorito C, et al. Prognostic factors of ‘high-grade’ Ta bladder cancers according to the WHO 2004 classification: areE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 0 1 – 8 1 3
812